B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy

Br J Haematol. 2021 May;193(4):851-855. doi: 10.1111/bjh.17397. Epub 2021 Mar 13.
No abstract available

Keywords: T cells; cellular therapies; immunotherapy; myeloma therapy.

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • B-Cell Maturation Antigen / blood*
  • Combined Modality Therapy
  • Dexamethasone / administration & dosage
  • Disease-Free Survival
  • Female
  • Humans
  • Immune Checkpoint Inhibitors / administration & dosage
  • Immunotherapy, Adoptive*
  • Lenalidomide / administration & dosage
  • Male
  • Middle Aged
  • Multiple Myeloma* / blood
  • Multiple Myeloma* / mortality
  • Multiple Myeloma* / therapy
  • Neoplasm Proteins / blood*
  • Programmed Cell Death 1 Receptor / blood*
  • Receptors, Chimeric Antigen*
  • Survival Rate
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives

Substances

  • Antibodies, Monoclonal, Humanized
  • B-Cell Maturation Antigen
  • Immune Checkpoint Inhibitors
  • Neoplasm Proteins
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Receptors, Chimeric Antigen
  • TNFRSF17 protein, human
  • elotuzumab
  • Thalidomide
  • Dexamethasone
  • pomalidomide
  • pembrolizumab
  • Lenalidomide